抗合成酶综合征中的肺动脉高压:患病率、跨自身免疫病比较风险及对生存的影响
基于全球多中心医师报告注册队列,1868例抗合成酶综合征(ASyS)与2043例对照分析显示,ASyS中肺动脉高压(PH)患病率为8.9%,高于非ASyS肌炎、RA和IPAF,但与SSc和SLE无显著差异。PH与ASyS全因死亡风险独立相关(HR 2.52,95%CI 1.41-4.53),提示应重视ASyS患者的PH评估。
要点
- ASyS中PH患病率8.9%,高于非ASyS肌炎、RA和IPAF。
- ASyS合并PH的5年生存率降至88.3%,PH与死亡风险独立相关。
- ASyS患者应常规评估肺动脉高压,尤其合并ILD者。
核心结论
- ASyS中PH患病率为8.9%,且PH与全因死亡风险增加独立相关(HR 2.52,95%CI 1.41-4.53),强调在该人群中进行PH评估的重要性。
研究设计与样本
- 数据来自全球医师报告的多中心注册队列,纳入医师诊断的ASyS和/或抗合成酶抗体阳性患者,共分析1868例ASyS和2043例对照,来自103个中心。
- 采用比较分析和多变量logistic回归评估ASyS相对于其他疾病组的PH比值比,采用Cox比例风险模型评估与全因死亡的关联。
主要发现
- ASyS中PH患病率为8.9%,高于非ASyS肌炎(3%,P < 0.001)、RA(4%,P = 0.009)和IPAF(3%,P = 0.003),但与SSc(13%,P = 0.07)和SLE(11%,P = 0.57)无显著差异。
- 在校正年龄、性别、吸烟和ILD的多变量模型中,ASyS相比非ASyS肌炎(OR 1.91)和IPAF(OR 3.72)的PH比值更高,但低于SSc(OR 0.62)和SLE(OR 0.24)。
- ASyS的5年生存率为94%,合并PH者降至88.3%(P = 0.001)。
- PH与ASyS死亡风险增加独立相关,校正年龄、性别和ILD后HR为2.52(95%CI 1.41-4.53)。
关键数值与推荐
- ASyS中PH患病率8.9%,非ASyS肌炎3%(P < 0.001),RA 4%(P = 0.009),IPAF 3%(P = 0.003),SSc 13%(P = 0.07),SLE 11%(P = 0.57)。
- 多变量模型中ASyS相比非ASyS肌炎PH的OR为1.91,相比IPAF的OR为3.72,相比SSc的OR为0.62,相比SLE的OR为0.24。
- ASyS 5年生存率94%,合并PH者88.3%(P = 0.001);PH与死亡关联的HR为2.52(95%CI 1.41-4.53)。
临床怎么用
- 对ASyS患者应关注肺动脉高压的评估,尤其当存在提示PH的临床线索时。
- 合并PH的ASyS患者死亡风险升高,需加强风险分层与随访管理。
局限性
- 数据来自医师报告的多中心注册队列,PH诊断基于医师报告,可能存在诊断偏倚和报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-synthetase syndrome (ASyS) is a distinct entity within the myositis spectrum characterized by interstitial lung disease (ILD) which raises the concern of increased pulmonary vascular pressures. However, the prevalence of pulmonary hypertension (PH) in real-world ASyS populations remains unclear. We investigated the prevalence and impact of PH in ASyS. METHODS: Data were obtained from a worldwide, physician-reported multicentre registry based on physician-diagnosed ASyS and/or a positive anti-synthetase antibody. Comparative analyses and multivariable logistic regression assessed the odds of PH in ASyS relative to other disease groups. Cox proportional hazards models evaluated associations with all-cause mortality. RESULTS: A total of 1868 ASyS and 2043 controls from 103 centres were analysed. Prevalence of PH was 8.9% of ASyS, which was higher than in non-ASyS myositis (3%, P < 0.001), RA (4%, P = 0.009) and interstitial pneumonia with autoimmune features (IPAF 3%, P = 0.003), but not significantly different from SSc (13%, P = 0.07) or SLE (11%, P = 0.57). ASyS had higher odds of PH compared with non-ASyS myositis (OR 1.91) and IPAF (OR 3.72), but lower odds than SSc (OR 0.62) or SLE (OR 0.24), in multivariate models adjusted for age, sex, smoking and ILD. Five-year survival in ASyS was 94%, decreasing to 88.3% in those with PH (P = 0.001). PH remained associated with increased mortality in ASyS, independent of age, sex and ILD (HR 2.52, 95% CI 1.41-4.53). CONCLUSION: PH occurred in 8.9% of ASyS and was independently associated with increased mortality, highlighting the importance of PH evaluation in this population.
引用
- Bae SS, Rivero Gallegos D, Bozan F, et al. Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases and impact on survival. Rheumatology (Oxford). 2026. PMID: 42809241. doi:10.1093/rheumatology/keag543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。